Setup, so nobody has to ask: BCH · KP · New Zealand.
I suspect the honest answer is that it depends, in which case I would like to know on what.
Assume I can obtain either option without difficulty, so availability is not the deciding factor.
What is the actual trade-off, and does it matter at the scale I am working at?
Start by asking what you are optimising for, because cost per milligram, documentation depth and lead time do not have a common winner.
Compare documentation on a fixed checklist rather than by impression: lot specificity, method section, chromatogram availability, quantified content, water and counter-ion figures, and whether the code is on the vial.
Lead time and lane behaviour are supplier properties too and are easier to compare than analytical ones, because they need no laboratory at all.
Gradient slope, column chemistry and detection wavelength all affect the reported purity figure, which is why the method section is the part that makes results comparable.
Nothing here is medical advice, and research-use compounds are not approved for human use.
Compare content, not purity. Purity clusters and content does not.
edited 2 Mar 2026 by t_oyelaran — added the citation requested in comments
Analytical standards and reagents with traceable certificates. Every quantitative result you read inherits the accuracy of the standard behind it.
Shop standardsThe honest answer is that most claimed differences between reputable suppliers are inside inter-laboratory noise.
Submitting to different laboratories introduces a method difference that commonly exceeds the supplier difference. Gradient slope alone can move a reported purity figure by a per cent in either direction.
In practice, publish the method with the result. A comparison without the laboratory named and the submission dates given is not reproducible by anyone.
Use a fixed documentation checklist rather than an impression.
The relevant point is that two competent laboratories disagree by half a per cent on identical material, which is larger than most of the differences people argue about.
Sample size matters. One order each is an anecdote about six vials; three orders each over a year is the beginning of a comparison.
To compare properly: order the same compound at the same nominal strength from each supplier, submit all samples to the same laboratory in the same submission if possible, and ask for the same test set on each.
Content assay results across the published datasets vary considerably more between suppliers than purity does, which makes content the more discriminating axis.
No supplier on this site pays for its position, and the storefront links are marked nofollow and sponsored.
Price per milligram of measured peptide, not per milligram of label claim.
A single member running three suppliers on one method is worth more than thirty members running one supplier each.
Cost per milligram of actual peptide is the honest price comparison, which means dividing by measured content rather than by label claim.
The caveat is that a comparison is a snapshot of the lots compared, and lots change.
Name the laboratory and the dates or the comparison cannot be reproduced.
This is the question where methodology matters more than the conclusion.
Content is the more discriminating measurement than purity for supplier comparison, because purity clusters tightly among competent suppliers and content does not.
The ratings on this site are a community opinion average on a ten-point scale and are not reconciled with any other community's figures.
Comparisons drawn from different laboratories at different times are weaker evidence than most people treat them as.
One laboratory, one method, one submission. Otherwise it is not a comparison.
Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.